Kidney Cancer

In closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.

Panelists discuss the dosing schedule and patient education related to tivozanib, along with indications for potential treatment switch based on toxicity management and patient well-being.

African American and Hispanic patients with clear cell renal cell carcinoma may be less likely to receive treatment with immune checkpoint inhibitors than White patients, says Solomon Woldu, MD.

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.

Dr Thomas Hutson outlines the diagnosis and staging of renal cell carcinoma, the surgical and non-surgical treatment options, and notes that while the majority of cases are potentially curable, 20-25% of patients present with or later develop metastatic disease.

Thomas Hutson, DO, PharmD, discusses renal cell carcinoma, including its epidemiology, risk factors, subtypes, and management approaches, in a dialogue with his clinical nurse, Kacie Ellis, RN, and his patient, Mr. Cesar Fuentes.

Perspectives on the adverse events and management of tivozanib, covering common and serious toxicities with an emphasis on a multidisciplinary approach to optimize patient care and treatment benefits.

Experts from the Dana-Farber Cancer Institute delve into the TIVO-3 trial, discussing the design, outcomes, and nuances of tivozanib as a treatment option for refractory kidney cancer.

Expert insight into monitoring patients with advanced kidney cancer, covering the frequency of clinic visits, blood work, and CT scans, as well as signs and symptoms that might indicate disease progression.

Reviewing the case of a case of a 73-year-old man with metastatic clear cell kidney cancer, experts discuss second-line treatment options informed by prior treatment response, patient goals, and adverse event profiles.

Insight into the importance of patient-centered care, highlighting the role of a multidisciplinary team in managing advanced renal cell carcinoma and addressing questions regarding alternative medications.

Key opinion leaders reflect on treatment approaches for renal cell carcinoma in light of factors like risk classification, symptom severity, and patient preferences, with considerations ranging from active surveillance to systemic combination therapies.

Expert discussion focused on approved therapies for first-line kidney cancer treatment including combination therapies, immunotherapy, and tyrosine kinase inhibitors (TKIs) in various clinical scenarios.

Join Wenxin (Vincent) Xu, MD, and his team at Dana-Farber Cancer Institute as they explore strategies for diagnosing and stratifying renal cell carcinoma, reviewing a clinical scenarios and best practices in workup.

Pembrolizumab plus lenvatinib yields clinically relevant efficacy in clear cell renal cell carcinoma subgroups based on site of metastasis and number of metastatic sites in the phase 3 CLEAR trial.

Belzutifan vs everolimus saw increased progression-free survival and objective response rate in patients with pretreated advanced clear cell renal cell carcinoma.

Belzutifan plus cabozantinib showed continued anti-tumor activity in patients with clear cell renal cell carcinoma.

Brian I. Rini, MD, led a panel where he and his colleagues discussed the results of the CLEAR trial and its implications in renal cell carcinoma.

Data from the phase 3 LITESPARK-005 trial support the supplemental new drug application for belzutifan as a treatment for patients with advanced renal cell carcinoma.

Robert Motzer, MD, led an expert panel to discuss the phase 3 CONTACT-03 which examined patients with renal cell carcinoma.

Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.

Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.

Centering discussion on sarcomatoid and rhabdoid non-clear cell renal cell carcinoma, panelists consider frontline IO-based regimens and their value in this setting.

A brief discussion centered on optimal treatment strategies for patients with chromophobe or papillary kidney cancers.

Switching its focus to non-clear cell RCC, the panel reviews data presented at ASCO 2023 on KEYNOTE-B61, combining lenvatinib + pembrolizumab in this setting.

The primary end point of progression-free survival was met in the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in patients with renal cell carcinoma.

Panelists shed light on key factors that help to inform the selection of frontline therapy in patients with advanced clear cell renal cell carcinoma.

In the context of the available frontline treatment armamentarium for advanced clear cell RCC, key opinion leaders consider how they would select or sequence therapy.

Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice.